Market Overview

Sunesis Pharmaceuticals Announces Global Licenses for Two Kinase Inhibitor Programs


Sunesis Pharmaceuticals (Nasdaq: SNSS) today announced that it has expanded its hematology franchise through separate global licensing agreements for two preclinical kinase inhibitor programs. The first agreement, with Biogen Idec (Nasdaq: BIIB), is for global commercial rights to SNS-062, a potent and selective non-covalently binding oral inhibitor of BTK (Bruton's tyrosine kinase).

See full press release

Posted-In: News Guidance Management Global


Related Articles (BIIB + SNSS)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial

US Stock Futures Up; Alcoa Earnings, Jobless Claims Data In Focus

Athersys Granted New Patents in Japan for Stem Cell, Regenerative Medicine Technology